Mucormycosis

• Fungal infection (2000 cases/year USA) caused by Mucorales in immunocompromised patients (e.g. uncontrolled diabetes, neutropenia, organ transplantation) 

• Increased reported incidents in USA, European, and Indian hospitals (Kontoyiannis, et al. CID 2000; Chakrabarti, A et al. Postgrad Med J 2009)

• Outbreaks in natural disasters (Indian Ocean Tsunami, Joplin Tornado) and among injured soldiers with IED sustained injuries (Andresen D et al. Lancet 2005; NeblettFanfairR, et al. N EnglJ Med 2012; WarkentienT, et al. CID 2012) 

• High mortality (50-100%) despite disfiguring surgery and current anti-fungal therapy

• Lack of rapid diagnostic tools for the disease

Candida auris

• C. auris began spreading in the United States in 2015. Reported cases increased 318% in 2018 when compared to the average number of cases reported in 2015 to 2017. 

• C. auris has been emerged now in more than 35 countries.

• 90% Isolates resistant to at least one antifungal.

• 30% Isolates resistant to at least two antifungals 

A. baumannii 

• Approximately 15,000 cases/year, which could add up to $300M-$500M revenues/ year.

• In 2017, carbapenem-resistant Acinetobacter caused an estimated 8,500 infections in hospitalized patients and 700 estimated deaths in the United States [Source: 2019 AR Threats Report]. 

• $281M Estimated attributable healthcare costs in 2017